OncoMed: Cowen & Company Healthcare Conference (OncoMed) - Mar 7, 2014 - "Vantictumab"; "Interim Phase 1 Clinical Data: Ongoing Phase 1a Study, N=29 (Dose levels: 0.5 to 15 mg/kg, Safety: Vantictumab is well tolerated, Effective bone protection strategy, Biomarker: Modulation of WNT pathway in patient samples, Efficacy: Single-agent activity in 3/3 NET pts (pNET and Carcinoid)" "
P1 data • Oncology
|